Advances in pharmacotherapies for axial spondyloarthritis.
Fiche publication
Date publication
juin 2023
Journal
Expert opinion on pharmacotherapy
Lien Pubmed
Résumé
Axial spondyloarthritis (axSpA) refers to an inflammatory rheumatic disease that mainly affects the axial skeleton and leads to progressive radiographic changes of the sacroiliac joints and spine. axSpA is currently subdivided into the radiographic (r-axSpA) and non-radiographic (nr-axSpA) form. Both forms are associated with musculoskeletal pain, restriction of spinal mobility, specific extra-musculoskeletal manifestations and overall, altered quality of life. The therapeutic management of axSpA is currently well standardized.
Mots clés
Nsaids, axial spondyloarthritis, biological agents, pharmacological treatments, recommendations
Référence
Expert Opin Pharmacother. 2023 06 15;: